MedTrace Logo

Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer

NCT03526510 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2022-03-08

No results posted yet for this study

Summary

Randomized trial comparing 2 external beam radiotherapy fractionation schemes in patients with localized high risk prostate cancer. Primary endpoint is acute toxicity.

Conditions

Interventions

RADIATION

Conventionally Fractionated versus Hypofractionated Boost

Sponsors & Collaborators

  • Dr. Patrick Cheung

    lead OTHER

Principal Investigators

  • Patrick Cheung, MD · Toronto Sunnybrook Regional Cancer Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2021-11-30
Completion
2024-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03526510 on ClinicalTrials.gov